MaaT013: The First Phase 3 Trial for Microbiome Therapy in Hemato-Oncology
Time: 9:30 am
day: Conference Day One - 7am to 10am
Details:
- Discussing the ongoing pivotal Phase 3 ARES trial for MaaT013 in patients with acute Graft-versus-Host Disease (GI-aGvHD) and its significance as the first global Phase 3 trial for a microbiome-based therapy in hemato-oncology
- Highlighting the Orphan Drug Designation from both the FDA and EMA, and the positive outcomes from the Data Safety Monitoring Board (DSMB) review.
- Exploring the positive Phase 3 ARES results, evaluating MaaT013’s unprecedented efficacy as a third-line treatment for GI-aGvHD
